Non-small cell lung cancer: Clinical value of new biological predictors

Lung Cancer

Volumn 17, Issue SUPPL. 1, 1997, Pages

  Graziano, Stephen L ^a  

^a SYRACUSE VA MEDICAL CENTER   (United States)

Author keywords

Lung cancer; Non small cell lung cancer; Prognosis

Indexed keywords

CELL NUCLEUS ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN P53;

CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; DIAGNOSTIC VALUE; FLOW CYTOMETRY; HUMAN; LUNG NON SMALL CELL CANCER; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030982728     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(97)00639-9     Document Type: Conference Paper

References (118)

1. Ginsberg RJ, Kris MG, Armstrong JG. Cancer of the lung. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer, Principles and Practice of Oncology (ed 4). Philadelphia: PA, Lippincott, 1993: pp. 673-758.
2. Gail MH, Eagan RT, Feld R, Ginsberg R, Goodell B, Hill L, Holmes EC, Lukeman JM, Mountain CF, Oldham RK, Pearson RG, Wright PW, Lake WH, Lung Cancer Study Group. Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the lung cancer study group. Cancer 1984; 54: 1802-1813.
3. Lipford EH, Eggleston JC, Lillemoe KD, Sears DL, Moor GW, Baker RR. Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung. Am J Surg Pathol 1984; 8: 357-365.
4. Takise A, Kodama T, Shimosato Y, Watanbe S, Suemasu K. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer 1988; 61: 2083-2088.
5. Isobe H, Miyamoto H, Shimizu T, Haneda H, Hashimoto M, Inoue K, Mizuno S, Kawakami Y. Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer 1990; 65: 1391-1395.
6. Zimmerman PV, Bint MH, Hawson GAT, Parsons PG. Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet 1987; 2(8558): 530-533.
7. Slebos RJC, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJLM, Wagenaar SS, Vanderschueren RGJRA, van Zandwijk, Mooi WJ, Bos JL, Rodenhuis S. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323: 561-565.
8. Harada M, Dosaka-Akita H, Miyamoto, Kuzumaki N, Kawakami Y. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 1992; 69: 72-77.
9. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990; 50: 5184-5191.
10. Lee JS, Ro JY, Sahin AA, Hong WK, Brown BW, Mountain CF, Hittelman WN. Expression of blood-group antigen A - a favorable prognostic factor in non-small cell lung cancer. N Engl J Med 1991; 324: 1084-1090.
11. Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M. Niimi T, Shimokata K, Yamakawa K, Nakamura Y, Ueda R, Takahasi T. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993; 53: 1-4.
12. Richardson GE, Johnson BE. The biology of lung cancer. Semin Oncol 1993; 20: 105-127.
13. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89(suppl): 225S-232S.
14. Bulzebruck H, Bopp R, Drings P, Bauer E, Krysa S, Probst G, van Kaick G, Muller KM, Vogt-Moykopf I. New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 1992; 70: 1102-1110.
15. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65: 25-32.
16. Pater JL, Loeb M. Nonanatomic prognostic factors in carcinoma of the lung: a multivariate analysis. Cancer 1982; 50: 326-331.
17. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P, Klatersky J. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin Oncol 1995; 13: 1221-1230.
18. Sorensen JB, Badsber JH. Prognostic factors in resected stage I and II adenocarcinoma of the lung. J Thorac Cardiovasc Surg 1990; 99: 218-226.
19. Harpole DH, Herndon JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995; 55: 51-56.
20. Nesbitt JC, Putnam JB, Walsh GL, Roth JA, Mountain CF. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 1995; 60: 466-472.
21. Thomas PA, Piantadosi A. Postoperative T1NO non-small cell lung cancer - squamous versus nonsquamous recurrences. J Thorac Cardiovasc Surg 1987; 94: 349-354.
22. Martini N, Bains MS, Burt NE, Zakowski MF, McCormack P, Rusch VW, Ginsberg RJ. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995; 109: 120-129.
23. Ichinose Y, Hara N, Ohta N, Yano T, Maeda K, Asoh H, Katsuda Y. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer? J Thorac Cardiovasc Surg 1993; 106: 90-94.
24. Shields TW. Prognostic significance of parenchymal lymphatic vessel and blood vessel invasion in carcinoma of the lung. Surg Gynecol Obstet 1983; 157: 185-190.
25. Roberts TE, Hasleton PS, Musgrove C, Swindell R, Lawson RAM. Vascular invasion in non-small cell lung carcinoma. J Clin Pathol 1992; 45: 591-593.
26. Sorensen JB, Olsen JE. Prognostic implications of histopathologic subtyping in patients with surgically treated stage I or II adenocarcinoma of the lung. J Thorac Cardiovasc Surg 1989; 97: 245-251.
27. Macchiarini P, Fontanini G, Hardin MJ, Chuanchieh H, Bigini D, Vignati S, Pingitore R, Angeletti CA. Blood vessel invasion by tumor cells predicts recurrence in completely resected T1NOMO non-small-cell lung cancer. J Thorac Cardiovasc Surg 1993; 106: 80-89.
28. Linnoila RI, Piantadosi S, Ruckdeschel JC. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. Chest 1994; 106: 367S-371S.
29. Graziano SL, Tatum AH, Newman NB, Oler A, Kohman LJ, Veit LJ, Gamble GP, Coleman MJ, Barmada S, O'Lear S. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer. Cancer Res 1994; 54: 2908-2913.
30. Harpole DH, Herndon JE, Young WG, Wolfe WG, Sabiston DC. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995; 76: 787-796.
31. Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988; 96: 440-447.
32. Pairolero PC, Williams DE, Bergstralh EJ, Piehler JM, Bernatz PE, Payne WS. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984; 38: 331-338.
33. Shimuzu J, Watanabe Y, Oda M, Hayashi Y, Ota Y, Morita K, Arano Y. Results of surgical treatment of stage I lung cancer. J Jpn Surg Soc 1993; 94: 505-510.
34. Sahin AA, Ro JY, El-Naggar AK, Lee JS, Ayala AG, Teague K, Hong WK. Flow cytometric analysis of the DNA content of non-small cell lung cancer. Ploidy as a significance prognostic indicator in squamous cell carcinoma of the lung. Cancer 1990; 65: 530-537.
35. Volm M, Hahn EW, Mattern J, Muller T, Vogt-Moykopf I, Weber E. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res 1988; 48: 2923-2928.
36. Filderman AE, Silvestri GA, Gatsonis C, Luthringer DJ, Honig J, Flynn SD. Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small cell lung cancer. Am Rev Respir Dis 1992; 146: 707-710.
37. Dazzi H, Thatcher H, Hasleton PS, Swindell R. DNA analysis by flow cytometry in nonsmall cell lung cancer: relationship to epidermal growth factor receptor, histology, tumour stage and survival. Respir Med 1990; 84: 217-223.
38. Van Bodegom PC, Baak JPA, Stroet-Van Galen C, Schipper NW, Wisse-Brekelmans ECM, Vanderschurene RGJRA, Wagenaar SSC. The percentage of aneuploid cells is significantly correlated with survival in accurately staged patients with stage I resected squamous cell lung cancer and long-term follow-up. Cancer 1989; 63: 143-147.
39. Schmidt RA, Rusch VW, Piantadosi S. A flow cytometric study of non-small cell lung cancer classified as T1NO. Cancer 1992; 69: 78-85.
40. Ten Velde GPM, Schutte B, Vermeulen A, Volovics A, Reynders M W, Blijham GH. Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small-cell lung cancer. Eur J Cancer Clin Oncol 1988; 24: 445-460.
41. Cibas ES, Melamed MR, Zaman MB, Kimmel M. The effect of tumor size and tumor cell DNA content on the survival of patients with stage I adenocarcinoma of the lung. Cancer 1989; 63: 1552-1556.
42. Graziano SL, Tatum AH, Gonchoroff NJ, Newman NB, Kohman LJ. Blood-group antigen A and flow cytometric analysis in resected early stage non-small cell lung cancer. Clin Cancer Res 1997; 3: 87-93.
43. Sabbatini R, Bandieri E, Lodi R, Frassoldati A, Barbieri F, Federico M. Flow cytometry DNA content in primary non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1993; 12: 347.
44. Rice TW, Bauer TW, Gephardt GN, Nedendorp SV, McLain DA, Kirby TJ. Prognostic significance of flow cytometry in non-small-cell lung cancer. J Thorac Cardiovasc Surg 1993; 106: 210-217.
45. Tungekar NF, Gatter KC, Dunnill MS, Mason DY. Ki-67 immunostaining and survival in operable lung cancer. Histopathology 1991; 19: 545-550.
46. Tateishi M, Ishida T, Mitsudomi T, Sugimachi K. DNA polimerase-alpha as a putative early relapse marker in non small cell lung cancer. An immunohistochemical study. Cancer 1991; 69: 925-929.
47. Scagliotti GV, Micela M, Gubetta L, Leonardo E, Cappia S, Borasio P, Pozzi E. Prognostic significance of Ki67 labeling in resected non small cell lung cancer. Eur J Cancer 1993; 29A: 363-365.
48. Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, Barne DM, Gillett CE, Camplejohn R, Dover R. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990; 162: 285-294.
49. Fontanini G, Macchiarini P, Pepe S, Ruggiero A, Hardin M, Bigini D, Vignati S, Pingitore R, Angeletti CA. The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer. Cancer 1992; 70: 1520-1527.
50. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992; 340: 145-146.
51. Ishida T, Kaneko S, Akazawa K, Tateishi M, Sugio T, Sugimachi K. Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients. Cancer Res 1993; 53: 5000-5003.
52. Walker RA. The histopathological evaluation of nucleolar organizer region proteins. Histopathology 1988; 12: 221-223.
53. Ebina M, Steinberg SM, Mulshine JL, Linnoila RI. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994; 54: 2496-2503.
54. Kay HEM, Wallace DN. A and B antigens of tumors arising from urinary epithelium. J Natl Cancer Inst 1961; 26: 1349-1365.
55. Limas C, Lange P, Fraley EE, Vessella RL. A, B, H antigens in transitional cell tumors of the urinary bladder. Cancer 1979; 44: 2099-2107.
56. Summers JL, Coon JS, Ward RM, Falor WH, Miller AA, Weinstein RS. Prognosis in carcinoma of the urinary bladder based upon tissue blood group ABH and Thomsen-Friedenreich antigen status and karyotype of the initial tumor. Cancer Res 1983; 43: 934-939.
57. Rice TW, Tubbs RR, Hoeltge GA, Kirby TJ, Meeker DP, Medendorp SV, Bukowski RM. Expression of blood group antigen A by stage I non-small cell lung carcinomas. Ann Thorac Surg 1995; 59: 568-572.
58. Dresler CN, Ritter JH, Wick MR, Roper CL, Patterson GA, Cooper JD. Immunostains for blood group antigens lack prognostic significance in T1 lung carcinoma. Ann Thorac Surg 1995; 59: 1069-1073.
59. Dabelsteen E, Vedtofte P, Hakomori S, Young WW. Accumulation of a blood group antigen precursor in oral premalignant lesions. Cancer Res 1983; 43: 1451-1454.
60. Orntoft TF, Wolf H, Clausen H, Dabelsteen E, Hakomori SI. Blood group ANH-related antigens in normal and malignant bladder urothelium: possible structural basis for the deletion of type-2 chain ABH antigens in invasive carcinomas. Int J Cancer 1989; 43: 774-780.
61. b antigens with survival in patients with carcinoma of the lung. N Engl J Med 1992; 327: 14-18.
62. Pantel K, Passlick B, Izbicki JR, Liewald R, Karg O, Riethmuller G. Expression of Lewis Y blood group precursor antigens on non-small cell lung carcinomas is associated with an unfavorable prognosis. Proc Am Soc Clin Oncol 1993; 12: 290.
63. Ogawa J, Sano A, Inoue H, Koide S. Expression of Lewis-related antigen and prognosis in stage I non-small cell lung cancer. Ann Thorac Surg 1995; 59: 412-415.
64. Lee JS, Hong WK. Prognostic factors in-lung cancer. N Engl J Med 1992; 327: 47-48.
65. Rodenhuis S, Van De Wetering MLM, Mooi WJ, Evers SG, van Zandwijk N, Bos JL. Mutational activation of the K-ras oncogene: a possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1989; 317: 929-935.
66. Bos JL. ras Oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
67. Rodenhuis S, Slebos RJC, Boot AJM, Evers SG, Mooi WJ, Wagenaar SSC, van Bodegom PC, Bos JL. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988; 48: 5738-5741.
68. Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K, Sasazuki T. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 1992; 52: 2903-2906.
69. Mitsudomi T, Steinberg SM, Oie HK, Mulshine JL, Phelps R, Viallet J, Pass H, Minna JD, Gazdar AF. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991; 51: 4999-5002.
70. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 1991; 6: 1353-1362.
71. Tsai CM, Chang KT, Perng RP, Mitsudomi T, Kadoyama C, Gazdar AF. Correlation of intrinsic chemoresistance of non-small cell lung cancer cell lines with HER-2/neu gene expression but not with ras mutations. J Natl Cancer Inst 1993; 85: 897-901.
72. Rosell R, Molina F, Moreno I, Martinez E, Pifarre A, Font A, Li S, Skacel Z, Gomez-Codina J, Camps C, Monzo M, de Anta JM. Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIa non-small cell lung cancer. Lung Cancer 1995; 12: S59-S70.
73. Keohavong P, De Michele MAA, Melacrinos AC, Landreneau RJ, Weyant RJ, Sigfried JM. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res 1996; 2: 411-418.
74. Rosell R, Li S, Moreno I, Ariza A, Sanchez JJ, Anton A, Gomez-Codina J, Font A, Camps C, Martinez E, Vadell C. Clinical implications of genotypic characterization of non-small cell lung cancer based on K-ras mutants. Proc Am Soc Clin Oncol 1994; 13: 325.
75. Miyamoto H, Harada M, Isobe H, Akita HD, Haneda H, Yamaguchi E, Kuzumaki N, Kawakami Y. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer. Cancer Res 1991; 51: 6346-6350.
76. Rodenhuis S, Slebos RJC. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992; 52: 2665S-2669S (suppl).
77. neu) in human non-small cell carcinomas of the lung. Cancer Res 1990; 50: 421-425.
78. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986; 319: 226-230.
79. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima H, Saito T, Toyoshima K. Similarity of protein encoded by the c-erbB-2 gene to epidermal growth factor receptor. Nature 1986; 319: 230-234.
80. Noguchi, M, Murakami M, Bennett W, Lupu R, Hui F, Harris CC, Gerwin BI. Biological consequences of overexpression of a transfected c-erbB-2 gene in immortalized human bronchial epithelial cells. Cancer Res 1993; 53: 2035-2043.
81. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 1991; 27: 1372-1375.
82. Scagliotti GV, Leonardo E, Cappia S, Masiero P, Micela M, Gubetta L, Pozzi E. Epidermal growth factor receptor and neu-oncogene expression in lung cancer. Proc Am Soc Clin Oncol 1993; 12: 328.
83. Kern J, Slebos R, Top B, Rodenhuis S, Lager D, Robinson R, Weiner D, Schwartz DA. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 1994; 93: 516-5520.
84. Volm M, Drings P, Wodrich W. Prognostic significance of the expression of c-fos, c-jun, and c-erbB-1 oncogene products in human squamous cell lung carcinomas. J Cancer Res Clin Oncol 1993; 119: 507-510.
85. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 1990; 50: 7077-7080.
86. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995; 13: 1009-1022.
87. Fung CY, Fisher DE. p53: from molecular mechanisms to prognosis in cancer. J Clin Oncol 1995; 13: 808-811.
88. Takahashi T, Nau MM, Chiba I, Birrer W, Rosenber RK, Vinocour M, Levitt M, Pass H, Gazdar AF. Minna JD. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246: 491-494.
89. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-679.
90. Takahashi T, Takahashi T, Suzuki H, Hida T, Sekido Y, Ariyoshi Y, Ueda R. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 1991; 6: 1775-1778.
91. Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, Reissman PT, Slamon W, Holmes EC Ninna JD. Mutations in the p.53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 1990; 5: 1603-1610.
92. Nitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Arnica D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD, Gazdar AF. p53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992; 7: 171-180.
93. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
94. Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K, Sekiya T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 1992; 52: 4799-4804.
95. Mitsudomi T, Lyama T, Kusano T, Ohsaki T, Nakanishi R, Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer [abstract]. Proc Am Assoc Cancer Res 1993; 34: 516.
96. Reichel MB, Ohgaki H, Petersen I Kleihues P. p53 mutations in primary human lung tumors and their metastases [abstract]. Proc Am Assoc Cancer Res 1993; 34: 534.
97. Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V. Nowak JA, McIntire D, Slamon D, Gazdar A, Minna J. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. Chest 1994; 106: 377S-381S.
98. Hiyoshi H, Matsuno Y, Kato H, Shimosato Y, Hirohashi S. Clinicopathological significance of nuclear accumulation of tumor suppressor gene p53 product in primary lung cancer. Jpn J Cancer Res 1992; 83: 101-106.
99. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992; 52: 4828-4831.
100. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992; 66: 735-738.
101. XU HJ, Quinlan DC, Davidson AG, Hu SX, Summers CL, Li J, Benedict WF. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst 1994; 86: 695-699.
102. Ebina M, Steinberg SM, Mulshine JL, Linnoila RI. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994; 54: 2496-2503.
103. Passlick B, Izbicki JR, Haussinger K, Thetter O. Pantel K. Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small-cell lung cancer. J Thorac Cardiovasc Surg 1995; 109: 1205-1211.
104. Volm M, Mattern J. Immunohistochemical detection of p53 in non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 1249.
105. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, Hittelman WN, Hong KH. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 1995; 13: 1893-1903.
106. Top B, Mooi WJ. Klaver SG, Boerrigter L, Wisman P, Elbers HRJ, Visser S, Rodenhuis S. Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int J Cancer 1995; 64: 83-91.
107. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF, Linnoila RI. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992; 7: 743-749.
108. Xu HJ, Cagle PT, Hu SX, Li J, Benedict WF. Altered retinoblastoma (RB) and p53 protein status as a synergistic prognostic factor in non-small cell lung carcinoma. Proc Am Assoc Cancer Res 1995; 36: 246.
109. Pezzella F, Turley H, Kuzu I, Tungekar MF. Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690-694.
110. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer.
111. Ritter JH, Dresler CM, Wick MR. Expression of bcl-2 protein in stage T1NOMO non-small cell lung carcinoma. Hum Pathol 1995; 26: 1227-1232.
112. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
113. Srivastava A, Laidler P, Davies RP, Horgan K, Lughes LE. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma: a quantitative histologic study. Am J Pathol 1988; 133: 419-423.
114. Weidner H, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
115. Macchiarini P, Fontanini G, Dulmet E, de Montpreville V, Chapelier AR, Cerrina J, Ladurie FLR, Dartevelle PG. Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann Thorac Surg 1994; 57: 1534-1539.
116. Fontanini G, Bigini D, Vignati S, Basolo F, Mussi A, Lucchi M, Chine S, Angeletti CA, Harris AL, Bevilacqua. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 1995; 177: 57-63.
117. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991; 83: 154-155.
118. Strauss GM, Kwiatkowski DJ, Harpole DH, Lynch TJ, Skarin AT, Sugarbaker DJ. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol 1995; 13: 1265-1279.